Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.

Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.

Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.

PMID:
28646080
2.

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective.

Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H.

Drug Metab Dispos. 2016 Oct;44(10):1720-30. doi: 10.1124/dmd.116.071076. Epub 2016 Jul 15.

3.

Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.

Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-Perez J, Salituro G, Palamanda J, Fernandis A, Ng CK, Liaw A, Savage MJ, Evers R.

Drug Metab Dispos. 2015 Jun;43(6):851-63. doi: 10.1124/dmd.115.063347. Epub 2015 Mar 26.

4.

Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.

Marcantonio EE, Ballard J, Gibson CR, Kassahun K, Palamanda J, Tang C, Evers R, Liu C, Zajic S, Mahon C, Mostoller K, Hreniuk D, Mehta A, Morris D, Wagner JA, Stoch SA.

J Clin Pharmacol. 2014 Nov;54(11):1280-9. doi: 10.1002/jcph.338. Epub 2014 Jun 25.

PMID:
24895078
5.

Pharmacological evaluation of selective α2c-adrenergic agonists in experimental animal models of nasal congestion.

Jia Y, Mingo GG, Hunter JC, Lieber GB, Palamanda JR, Mei H, Boyce CW, Koss MC, Yu Y, Cicmil M, Hey JA, McLeod RL.

J Pharmacol Exp Ther. 2014 Apr;349(1):75-84. doi: 10.1124/jpet.113.210666. Epub 2014 Feb 3.

6.

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.

Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T.

Drug Metab Dispos. 2013 Mar;41(3):668-81. doi: 10.1124/dmd.112.049668. Epub 2013 Jan 4.

7.

Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.

Nagy LD, Mocny CS, Diffenderfer LE, Hsi DJ, Butler BF, Arthur EJ, Fletke KJ, Palamanda JR, Nomeir AA, Furge LL.

Drug Metab Dispos. 2011 Jun;39(6):974-83. doi: 10.1124/dmd.110.037630. Epub 2011 Mar 21.

8.

Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A).

Corboz MR, Rivelli MA, McCormick KD, Wan Y, Shah H, Umland S, Lieber G, Jia Y, McLeod RL, Morgan C, Varty GB, Wu J, Feng KI, Boyce CW, Aslanian RG, Palamanda J, Nomeir AA, Korfmacher W, Hunter JC, Anthes JC, Hey JA.

J Pharmacol Exp Ther. 2011 Apr;337(1):256-66. doi: 10.1124/jpet.110.175794. Epub 2011 Jan 13.

9.

Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion.

Palamanda JR, Mei H, Morrison R, McLeod RL, McCormick K, Corboz M, Xu X, Korfmacher W, Broske L, Nomeir AA.

Drug Metab Lett. 2010 Apr;4(2):56-61.

PMID:
20446910
10.

Loratadine and montelukast administered in combination produce decongestion in an experimental feline model of nasal congestion.

McLeod RL, Mingo GG, Xu X, Palamanda J, Hunter JC, Jia Y.

Am J Rhinol Allergy. 2009 Nov-Dec;23(6):e17-22. doi: 10.2500/ajra.2009.23.3365. Epub 2009 Sep 18.

PMID:
19769798
11.

Evaluation of CYP1A1 and CYP2B1/2 m-RNA induction in rat liver slices using the NanoString technology: a novel tool for drug discovery lead optimization.

Palamanda JR, Kumari P, Murgolo N, Benbow L, Lin X, Nomeir AA.

Drug Metab Lett. 2009 Aug;3(3):171-5. Epub 2009 Aug 1.

PMID:
19702544
12.

High-throughput evaluation of CYP1A1 and 2B1 induction in rat liver slices using a semi-automated system.

Palamanda JR, Lin X, Kumari P, Nomeir AA.

Drug Metab Lett. 2009 Apr;3(2):108-14.

PMID:
19601872
13.

Co-induction of CYP3A12 and 3A26 in dog liver slices by xenobiotics: species difference between human and dog CYP3A induction.

Chen J, Tran C, Xiao L, Palamanda J, Klapmuts T, Kumari P, Lin X, Wang EJ, Gu YZ, Humphries M, Uss AS, Cheng KC.

Drug Metab Lett. 2009 Jan;3(1):61-6.

PMID:
19356119
14.

Temporal evaluation of CYP mRNA in mice administered with prototypical P450 inducers: comparison with conventional protein/enzyme methods.

Wang EJ, Mandakas G, Palamanda J, Lin X, Kumari P, Chu I, Soares A, Smith RJ, Snyder RD, Gu YZ.

Drug Chem Toxicol. 2008;31(4):501-13. doi: 10.1080/01480540802390825 .

PMID:
18850359
15.

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M.

J Med Chem. 2008 Jun 12;51(11):3061-4. doi: 10.1021/jm800180e. Epub 2008 May 1.

PMID:
18447380
16.

Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.

Chelliah MV, Chackalamannil S, Xia Y, Eagen K, Clasby MC, Gao X, Greenlee W, Ahn HS, Agans-Fantuzzi J, Boykow G, Hsieh Y, Bryant M, Palamanda J, Chan TM, Hesk D, Chintala M.

J Med Chem. 2007 Oct 18;50(21):5147-60. Epub 2007 Sep 14.

PMID:
17854166
17.

Metabolism-based identification of a potent thrombin receptor antagonist.

Clasby MC, Chackalamannil S, Czarniecki M, Doller D, Eagen K, Greenlee W, Kao G, Lin Y, Tsai H, Xia Y, Ahn HS, Agans-Fantuzzi J, Boykow G, Chintala M, Foster C, Smith-Torhan A, Alton K, Bryant M, Hsieh Y, Lau J, Palamanda J.

J Med Chem. 2007 Jan 11;50(1):129-38.

PMID:
17201416
18.

Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo.

Cui X, Thomas A, Han Y, Palamanda J, Montgomery D, White RE, Morrison RA, Cheng KC.

J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43. Epub 2005 Apr 1.

PMID:
16125621
19.

Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.

Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, Pissarnitski DA, Stamford AW, Wang Y, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P.

Bioorg Med Chem Lett. 2005 May 2;15(9):2365-9.

PMID:
15837326
20.

SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.

Pissarnitski DA, Asberom T, Boyle CD, Chackalamannil S, Chintala M, Clader JW, Greenlee WJ, Hu Y, Kurowski S, Myers J, Palamanda J, Stamford AW, Vemulapalli S, Wang Y, Wang P, Wu P, Xu R.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1291-4.

PMID:
14980684
21.

Assessment of temporal biochemical and gene transcription changes in rat liver cytochrome P450: utility of real-time quantitative RT-PCR.

Goodsaid FM, Palamanda JR, Montgomery D, Mandakas G, Gu C, Li Z, You X, Norton L, Smith R, Chu I, Soares T, Alton K, Kishnani NS, Rosenblum IY.

Pharm Res. 2003 Sep;20(9):1373-80.

PMID:
14567630
22.

A high-throughput cell-based reporter gene system for measurement of CYP1A1 induction.

Cui X, Palamanda J, Norton L, Thomas A, Lau YY, White RE, Cheng KC.

J Pharmacol Toxicol Methods. 2002 May-Jun;47(3):143-51.

PMID:
12628305
23.

Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.

Wang Y, Chackalamannil S, Hu Z, Boyle CD, Lankin CM, Xia Y, Xu R, Asberom T, Pissarnitski D, Stamford AW, Greenlee WJ, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3149-52.

PMID:
12372521
24.

Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.

Palamanda JR, Casciano CN, Norton LA, Clement RP, Favreau LV, Lin C, Nomeir AA.

Drug Metab Dispos. 2001 Jun;29(6):863-7.

25.

Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.

Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC.

Drug Metab Dispos. 2001 May;29(5):748-53.

26.
27.
28.

Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli.

Hickman D, Palamanda JR, Unadkat JD, Sim E.

Biochem Pharmacol. 1995 Aug 25;50(5):697-703.

PMID:
7669073
29.

Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.

Palamanda JR, Hickman D, Ward A, Sim E, Romkes-Sparks M, Unadkat JD.

Drug Metab Dispos. 1995 Apr;23(4):473-7.

PMID:
7600914
30.

Modulation of rat heart mitochondrial function and the production of reactive oxygen by vitamin E deficiency.

Paraidathathu T, Palamanda J, Kehrer JP.

Toxicology. 1994 May 31;90(1-2):103-14.

PMID:
8023335
31.
32.

Inhibition of protein carbonyl formation and lipid peroxidation by glutathione in rat liver microsomes.

Palamanda JR, Kehrer JP.

Arch Biochem Biophys. 1992 Feb 14;293(1):103-9.

PMID:
1731626

Supplemental Content

Loading ...
Support Center